» Articles » PMID: 32815325

MRNA Delivery Using Bioreducible Lipidoid Nanoparticles Facilitates Neural Differentiation of Human Mesenchymal Stem Cells

Overview
Date 2020 Aug 21
PMID 32815325
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSCs) are widely used in regenerative medicine and tissue engineering and delivering biological molecules into MSCs has been used to control stem cell behavior. However, the efficient delivery of large biomolecules such as DNA, RNA, and proteins into MSCs using nonviral delivery strategies remains an ongoing challenge. Herein, nanoparticles composed of cationic bioreducible lipid-like materials (lipidoids) are developed to intracellularly deliver mRNA into human mesenchymal stem cells (hMSCs). The delivery efficacy to hMSCs is improved by adding three excipients including cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol (DSPE-PEG) during lipidoid nanoparticle formulation. Using an optimized lipidoid formulation, Cas9 mRNA and single guide RNA (sgRNA) targeting neuron restrictive silencing factor (NRSF) are delivered to hMSCs, leading to successful neural-like differentiation as demonstrated by the expression of synaptophysin (SYP), brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), and neuron-specific growth-associated protein (SCG10). Overall, a synthetic lipid formulation that can efficiently deliver mRNA to hMSCs is identified, leading to CRISPR-based gene knockdown to facilitate hMSCs transdifferentiation into neural-like lineage.

Citing Articles

Lipid-based nanoparticles for drug delivery in Parkinson's disease.

Cai H, Liu D, Xue W, Ma L, Xie H, Ning K Transl Neurosci. 2024; 15(1):20220359.

PMID: 39654878 PMC: 11627081. DOI: 10.1515/tnsci-2022-0359.


Biomaterials for in situ cell therapy.

Wang C, Wang S, Kang D, Dong Y BMEmat. 2024; 1(3).

PMID: 39574564 PMC: 11581612. DOI: 10.1002/bmm2.12039.


Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach.

Haghighi E, Abolmaali S, Dehshahri A, Mousavi Shaegh S, Azarpira N, Tamaddon A J Nanobiotechnology. 2024; 22(1):710.

PMID: 39543630 PMC: 11566655. DOI: 10.1186/s12951-024-02972-w.


Advances in the study of LNPs for mRNA delivery and clinical applications.

Wang B, Shen B, Xiang W, Shen H Virus Genes. 2024; 60(6):577-591.

PMID: 39172354 DOI: 10.1007/s11262-024-02102-6.


LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing.

Xue Y, Zhang Y, Zhong Y, Du S, Hou X, Li W Nat Commun. 2024; 15(1):739.

PMID: 38272900 PMC: 10811230. DOI: 10.1038/s41467-024-45094-5.